IMUX (Immunic) Cyclically Adjusted FCF per Share: $-180.96 (As of Mar. 2026)


IMUX Immunic Inc IMUX
32 GF Score
Price $14.81
! 3 Warning Signs
View Full Analysis

What is Immunic Cyclically Adjusted FCF per Share?

Immunic IMUX -3.52% 32 Cyclically Adjusted FCF per Share is $-180.96 as of Mar. 2026. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Immunic's adjusted free cash flow per share for the three months ended in Mar. 2026 was $-0.574. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-180.96 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 28.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Immunic was 28.60% per year. The lowest was 28.60% per year. And the median was 28.60% per year.

As of today (2026-07-01), Immunic's current stock price is $14.81. Immunic's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $-180.96. Immunic's Cyclically Adjusted Price-to-FCF of today is .


Immunic  (NAS:IMUX) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Immunic Cyclically Adjusted FCF per Share Related Terms


Immunic Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Immunic's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic Cyclically Adjusted FCF per Share Chart

Immunic Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -536.19 -397.39 -302.29 -195.58

Immunic Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -274.51 -240.07 -213.74 -195.58 -180.96

IMUX vs WHWK, ALEC, TTRX: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Immunic's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunic Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Immunic's Cyclically Adjusted Price-to-FCF falls into.


IMUX
32GF Score
Immunic Inc IMUX
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunic Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Immunic's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.574/330.2130*330.2130
=-0.574

Current CPI (Mar. 2026) = 330.2130.

Immunic Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -113.679 241.018 -155.749
201609 -103.304 241.428 -141.294
201612 -115.263 241.432 -157.648
201703 -136.390 243.801 -184.732
201706 -96.991 244.955 -130.749
201709 -90.434 246.819 -120.989
201712 -94.632 246.524 -126.757
201803 -124.755 249.554 -165.077
201806 -118.292 251.989 -155.013
201809 -125.906 252.439 -164.696
201812 -43.896 251.233 -57.696
201903 -62.635 254.202 -81.364
201906 -11.372 256.143 -14.660
201909 -5.977 256.759 -7.687
201912 -6.137 256.974 -7.886
202003 -10.263 258.115 -13.130
202006 -7.309 257.797 -9.362
202009 -6.501 260.280 -8.248
202012 -6.737 260.474 -8.541
202103 -6.121 264.877 -7.631
202106 -13.344 271.696 -16.218
202109 -6.959 274.310 -8.377
202112 -7.918 278.802 -9.378
202203 -7.356 287.504 -8.449
202206 -5.220 296.311 -5.817
202209 -4.473 296.808 -4.976
202212 -3.942 296.797 -4.386
202303 -4.493 301.836 -4.915
202306 -4.501 305.109 -4.871
202309 -3.894 307.789 -4.178
202312 -3.182 306.746 -3.425
202403 -2.467 312.332 -2.608
202406 -1.700 314.175 -1.787
202409 -2.058 315.301 -2.155
202412 -2.281 315.605 -2.387
202503 -2.153 319.799 -2.223
202506 -1.865 322.561 -1.909
202509 -1.042 324.800 -1.059
202512 -0.993 324.054 -1.012
202603 -0.574 330.213 -0.574

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $-180.96 mean?
Immunic (IMUX) has a Cyclically Adjusted FCF per Share of $-180.96 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Immunic and its competitors.
Is Immunic's Cyclically Adjusted FCF per Share too high?
Immunic's current Cyclically Adjusted FCF per Share is $-180.96. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's Cyclically Adjusted FCF per Share compare to WHWK and ALEC?
Immunic's Cyclically Adjusted FCF per Share of $-180.96 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Immunic and its competitors. Immunic's current Cyclically Adjusted FCF per Share is $-180.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current Cyclically Adjusted FCF per Share of $-180.96. The current Cyclically Adjusted FCF per Share is $-180.96. Immunic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Immunic (IMUX), the current Cyclically Adjusted FCF per Share is $-180.96 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunic Business Description

Other Exchanges 10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for IMUX

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.81
Price